Skip to content Skip to footer
Subscribe Now

NEWS

Solventum
Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B
Shots: Thermo Fisher has entered into definitive agreement with Solventum to acquire its purification & filtration business for ~$4.1B in cash, adding value to its upstream and downstream biologics development & manufacturing Transaction is expected to close by the end of 2025, pending regulatory approval & customary closing conditions Solventum's purification and filtration unit…
February 26, 2025
Elanco
Medgene collaborates with Elanco for H5N1 Cattle Vaccine
Shots: Medgene has entered into an agreement with Elanco to commercialize Medgene’s highly pathogenic avian influenza (HPAI/H5N1) vaccine in the US for dairy cattle Medgene's vaccine has met all USDA platform tech guidelines & is in final review for conditional approval, with manufacturing supply ready for deployment upon approval HPAI vaccine is developed…
February 26, 2025
Merck
Merck Reports the US FDA’s sBLA Acceptance of Neoadjuvant Keytruda with Priority Review for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Shots: The US FDA has accepted sBLA & granted priority review to neoadj. Keytruda followed by adj. Keytruda + SoC radiotherapy ± cisplatin & then as a single agent to treat operable LA-HNSCC (PDUFA: Jun 23, 2025) sBLA was based on P-III (KEYNOTE-689) trial data assessing neoadj. Keytruda (200mg, IV, Q3W × 2 cycles), followed by…
February 26, 2025
summit therapeutics &pfizer
Summit Therapeutics Partners with Pfizer to Assess Ivonescimab in Combination with Pfizer’s ADCs for Various Solid Tumor Settings
Shots: Summit has entered into a clinical trial collaboration with Pfizer to assess safety & anti-tumor activity of ivonescimab with multiple Pfizer’s vedotin ADCs in solid tumors; trials are expected to initiate in mid-2025 As per the deal, Summit will supply ivonescimab for proposed trials & Pfizer will handle operations, with both firms jointly…
February 25, 2025
Boehringer Ingelheim
Boehringer Ingelheim Introduces Vaxxitek HVT+IBD+H5 Vaccine Against Marek’s Disease, Infectious Bursal Disease and H5 Avian Influenza
Shots: BI has launched Vaxxitek HVT+IBD+H5, a trivalent poultry vaccine against marek’s disease, infectious bursal disease & H5 avian influenza; commercially available in Egypt by Feb 2025 Trivalent vaccine uses BI's COBRA tech to create unique antigen for protection against prevalent H5 clades & is administered at the hatchery for early chick protection to avoid…
February 25, 2025
Load more